natgillin/translations-raw huggingface dataset:
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Keytruda have also been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Keytruda upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What benefits of Keytruda have been shown in studies?
Kakšne koristi zdravila Keytruda so se pokazale v študijah?
As for all medicines, data on the use of Keytruda are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Keytruda stalno spremljajo.
The company that markets Keytruda will provide patients with an information pack and alert card to inform them about the risks of potential immune-related side effects and give instructions on when to contact their doctor if they experience symptoms.
Podjetje, ki trži zdravilo Keytruda, bo bolnikom priskrbelo informativni bilten in opozorilno kartico z obvestilom o tveganjih neželenih učinkov na imunski sistem in navodili za posvetovanje z zdravnikom v primeru pojava simptomov.
An overview of Keytruda and why it is authorised in the EU
Pregled zdravila Keytruda in zakaj je odobreno v EU
Side effects reported with Keytruda are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Keytruda, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
When Keytruda is given alone the dose is either 200 mg every three weeks or 400 mg every six weeks.
Kadar se zdravilo Keytruda daje kot samostojno zdravilo, znaša odmerek bodisi 200 mg vsake tri tedne bodisi 400 mg vsakih šest tednov.
What is Keytruda and what is it used for?
Kaj je zdravilo Keytruda in za kaj se uporablja?
The average time that patients lived without their disease getting worse again was around 11 months.
Povprečno trajanje obdobja brez ponovnega poslabšanja bolezni je bilo okoli enajst mesecev.
Keytruda is mainly used for cancers that are advanced, have spread to other parts of the body (metastatic) or are not responding to other treatments.
Zdravilo Keytruda se uporablja predvsem pri tistih rakavih obolenjih, ki so napredovala, se razširila na druge dele telesa (so metastatska) ali se ne odzivajo na druga zdravila.
Other information about Keytruda
Druge informacije o zdravilu Keytruda
For more information about using Keytruda, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Keytruda glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with Keytruda?
Kakšna tveganja so povezana z zdravilom Keytruda?
Keytruda did not delay worsening of the disease compared with the other cancer medicines (time to disease worsening was 2 and 3 months respectively).
Zdravilo Keytruda ni upočasnilo poslabšanja bolezni v primerjavi z drugimi zdravili za zdravljenje raka (čas do poslabšanja bolezni je bil dva oziroma tri mesece).
The most common side effects of Keytruda given alone (which may affect more than 1 in 5 people) are tiredness, nausea (feeling sick) and diarrhoea.
Najpogostejši neželeni učinki zdravila Keytruda (ki se lahko pojavijo pri več kot 1 bolniku od 5) so utrujenost, navzeja (siljenje na bruhanje) in driska.
At 18 months, 81% of the patients given the combination were alive, compared with 71% in the sunitinib group.
Po 18 mesecih je bilo 81 % bolnikov, ki so prejemali kombinacijo zdravil, še vedno živih, v primerjavi z 71 % tistih, ki so prejemali sunitinib.
Some cancers can make a protein (PD-L1) that combines with PD-1 to switch off the activity of certain cells of the immune system (the body's natural defences) preventing them from attacking the cancer.
Nekatere vrste rakavih obolenj lahko povzročijo, da beljakovina (PD-L1), ki se veže na receptor PD-1, prekine dejavnost določenih celic imunskega sistema (naravnega obrambnega mehanizma telesa), s čimer jim prepreči napadanje rakavih celic.
The active substance in Keytruda, pembrolizumab, is a monoclonal antibody, a protein that has been designed to recognise and block a receptor (‘target') called PD-1.
Učinkovina zdravila Keytruda, pembrolizumab, je monoklonsko protitelo, tj. beljakovina, ki je bila zasnovana tako, da prepozna in zavre receptor (prijemališče), imenovan PD-1.
Keytruda can delay worsening of melanoma and improve survival.
Zdravilo Keytruda lahko upočasni slabšanje melanoma in podaljša preživetje.
Keytruda is also effective in combination treatment of a type of NSCLC known as ‘non-squamous' cancer, based on the type of cancer cells involved.
Zdravilo Keytruda je učinkovito tudi pri kombiniranem zdravljenju vrste nedrobnoceličnega pljučnega raka, znanega kot „neploščatocelični“ rak, glede na vrsto prisotnih rakavih celic.
The side effects with this medicine are manageable and are similar to those of various other cancer treatments.
Neželeni učinki tega zdravila so obvladljivi in podobni neželenim učinkom, ki se pojavljajo pri številnih drugih zdravilih za zdravljenje raka.
A second study looked at 834 patients with melanoma who received either Keytruda or another medicine, ipilimumab.
V drugi študiji so proučevali 834 bolnikov z melanomom, ki so prejemali zdravilo Keytruda ali drugo zdravilo, ipilimumab.
The doctor may delay doses if certain side effects occur or stop treatment altogether if side effects are severe.
Če se pojavijo nekateri neželeni učinki, bo zdravnik morda odložil nadaljnje odmerke ali popolnoma prekinil zdravljenje, če so neželeni učinki resni.
Results from a study of 540 previously treated patients with melanoma showed that 2 years after start of treatment, the disease had not worsened in 16% of patients treated with Keytruda compared with less than 1% of patients treated with chemotherapy.
Rezultati študije pri 540 predhodno zdravljenih bolnikih z melanomom so pokazali, da se dve leti po začetku zdravljenja bolezen ni poslabšala pri 16 % bolnikov, zdravljenih z zdravilom Keytruda, v primerjavi z manj kot 1 % bolnikov, zdravljenih s kemoterapijo.
By blocking PD-1, pembrolizumab stops the cancer switching off these immune cells, thereby increasing the immune system's ability to kill the cancer cells.
Pembrolizumab z zaviranjem receptorja PD-1 prepreči raku, da bi ta prekinil delovanje navedenih imunskih celic, s čimer poveča sposobnost imunskega sistema za uničevanje rakavih celic.
A study looked at 542 patients previously treated with platinum-based medicines who received either Keytruda or another cancer medicine chosen by the doctor (paclitaxel, docetaxel or vinflunine).
V študiji so proučevali 542 bolnikov, ki so se že zdravili z zdravili na osnovi platine in so prejemali zdravilo Keytruda ali drugo zdravilo za zdravljenje raka po izboru zdravnika (paklitaksel, docetaksel ali vinflunin).
For renal cell carcinoma, Keytruda is used in combination with other cancer medicines.
Pri zdravljenju raka ledvičnih celic se zdravilo Keytruda uporablja v kombinaciji z drugimi zdravili za zdravljenje raka.
A third study in 1,019 patients who had had surgery and who were at high risk for their cancer coming back compared Keytruda to placebo (a dummy treatment).
V tretji študiji, v katero je bilo vključenih 1 019 bolnikov, ki so imeli kirurški poseg in so bili izpostavljeni visokemu tveganju za ponovitev raka, so zdravilo Keytruda primerjali s placebom (zdravilom brez učinkovine).
Keytruda is also used to help prevent the cancer from coming back after patients had surgery to remove melanoma (adjuvant therapy).
Zdravilo Keytruda se uporablja tudi za preprečevanje ponovitve raka, potem ko je bil pri bolniku opravljen kirurški poseg odstranitve melanoma (adjuvantno zdravljenje).
For the full list of side effects and restrictions with Keytruda, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Keytruda glejte navodilo za uporabo.
After one and a half years of treatment, 72% of patients on Keytruda were still disease-free compared with 54% of patients on placebo.
Po enem letu in pol zdravljenja še vedno ni bilo znakov bolezni pri 72 % bolnikov, ki so prejemali zdravilo Keytruda, v primerjavi s 54 % bolnikov, ki so prejemali placebo.
Skin cancer
Kožni rak
In a further study of 559 patients with ‘squamous' NSCLC that had spread, patients given Keytruda with carboplatin and paclitaxel or nab-paclitaxel lived on average for 15.9 months compared with 11.3 months for patients given placebo with carboplatin and paclitaxel or nab-paclitaxel.
V nadaljnji študiji, v kateri je sodelovalo 559 bolnikov s ploščatoceličnim nedrobnoceličnim pljučnim rakom, ki se je razširil, so bolniki, ki so prejemali zdravilo Keytruda v kombinaciji s karboplatinom in paklitakselom ali nabpaklitakselom, v povprečju živeli 15,9 meseca v primerjavi z 11,3 meseca pri bolnikih, ki so prejemali placebo v kombinaciji s karboplatinom in paklitakselom ali nabpaklitakselom.
Urothelial cancer
Urotelijski rak
In this study, disease did not get worse for 5.1 months on average in patients taking Keytruda combination, 3.2 months in patients taking Keytruda alone and 5.0 months in patients taking other standard treatments.
V tej študiji se bolezen ni poslabšala povprečno 5,1 meseca pri bolnikih, ki so prejemali zdravilo Keytruda v kombinaciji s kemoterapijo, 3,2 meseca pri bolnikih, ki so prejemali zdravilo Keytruda kot samostojno zdravilo, in 5,0 meseca pri bolnikih, ki so prejemali druga standardna zdravljenja.
For the other cancers, Keytruda is only used on its own.
Pri drugih vrstah raka se zdravilo Keytruda uporablja le kot samostojno zdravilo.
Keytruda partially or completely clears cancer cells in classical Hodgkin lymphoma that has not improved or had returned after treatment with brentuximab vedotin, with or without an autologous stem cell transplantation.
Zdravilo Keytruda skupaj z avtologno presaditvijo matičnih celic ali brez nje delno ali popolnoma uniči rakave celice pri klasičnem Hodgkinovem limfomu, ki se po zdravljenju z brentuksimabom vedotinom ni izboljšal ali se je po tovrstnem zdravljenju ponovil.
In a study of 616 patients with non-squamous NSCLC that had spread, 69% of patients taking Keytruda with pemetrexed and platinum chemotherapy were alive at 11 months, compared with less than half of patients who had only pemetrexed and platinum chemotherapy.
V študiji pri 616 bolnikih z neploščatoceličnim nedrobnoceličnim pljučnim rakom, ki se je razširil, je 11 mesecev živelo 69 % bolnikov, ki so jemali zdravilo Keytruda skupaj s kemoterapijo s pemetreksedom in platino, in manj kot polovica bolnikov, ki so prejemali samo kemoterapijo s pemetreksedom in platino.
Keytruda is effective at improving survival or delaying the worsening of disease in patients with advanced cancers or cancers that have spread or come back.
Zdravilo Keytruda učinkovito izboljšuje preživetje ali odloži poslabšanje bolezni pri bolnikih z napredovalimi rakavimi obolenji ali rakavimi obolenji, ki so se razširila ali ponovila.
In a study of 861 patients with renal cell carcinoma, patients given Keytruda in combination with an already authorised medicine for renal cell carcinoma, axitinib, lived for around 15 months without their disease getting worse, compared with 11 months for patients who received treatment with another renal cell carcinoma medicine, sunitinib, which was used as a control treatment.
V študiji pri 861 bolnikih z rakom ledvičnih celic so bolniki, ki so prejemali zdravilo Keytruda v kombinaciji z že odobrenim zdravilom za zdravljenje raka ledvičnih celic, aksitinibom, živeli približno 15 mesecev brez poslabšanja bolezni v primerjavi z 11 meseci pri bolnikih, ki so se zdravili z drugim zdravilom za zdravljenje raka ledvičnih celic, sunitinibom, ki je bilo uporabljeno kot kontrolno zdravilo.
Before starting treatment, patients with NSCLC, previously untreated urothelial cancer or HNSCC should have tests to check their levels of PD-L1.
Pred začetkom zdravljenja je treba pri bolnikih z nedrobnoceličnim pljučnim rakom, predhodno nezdravljenim urotelijskim rakom ali ploščatoceličnim rakom glave in vratu s preiskavami preveriti ravni beljakovine PD-L1.
In some cancers, it is only given to patients whose tumours produce high levels of a protein known as PD-L1.
Pri nekaterih vrstah rakavih obolenj se daje samo bolnikom, pri katerih tumorji tvorijo večje količine beljakovine PD-L1.
Keytruda is also effective in delaying worsening of the disease and improving survival in patients with NSCLC that tested positive for the PD-L1 protein.
Zdravilo Keytruda je učinkovito tudi pri odlogu poslabšanja bolezni in izboljšanju preživetja bolnikov z nedrobnoceličnim pljučnim rakom, ki so pozitivni na beljakovino PD-L1.
How does Keytruda work?
Kako zdravilo Keytruda deluje?
Another study in 882 patients with HNSCC showed that Keytruda alone or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy is effective at prolonging patients' lives when HNSCC tests positive for a certain level of PD-L1.
Druga študija pri 882 bolnikih s ploščatoceličnim rakom glave in vratu je pokazala, da je zdravilo Keytruda kot samostojno zdravilo ali v kombinaciji s kemoterapijo s platino in 5-fluoroacilom (5-FU) učinkovito pri podaljševanju življenja bolnikov, pri katerih so bili testi za določeno raven beljakovine
Keytruda improves survival of patients with urothelial cancer.
Zdravilo Keytruda izboljša preživetje bolnikov z urotelijskim rakom.
Keytruda is given as an infusion (drip) into a vein.
Zdravilo Keytruda se daje z infundiranjem (kapalno infuzijo) v veno.
Keytruda was more effective in patients who tested strongly for PD-L1, with these patients living for 15 months on average, 5 months of which without their disease worsening.
Zdravilo Keytruda je bilo učinkovitejše pri bolnikih, pri katerih so bile s preiskavo ugotovljene večje količine beljakovine PD-L1, saj so ti bolniki v povprečju živeli 15 mesecev, od tega pet mesecev brez poslabšanja bolezni.
Keytruda is also effective in preventing melanoma from coming back in patients who have had surgery.
Zdravilo Keytruda je učinkovito tudi pri preprečevanju ponovitve melanoma pri bolnikih, pri katerih je bil opravljen kirurški poseg.
How is Keytruda used?
Kako se zdravilo Keytruda uporablja?
• renal cell carcinoma (a type of kidney cancer).
• raka ledvičnih celic (vrste raka ledvic).
Patients treated with Keytruda lived for up to 5.6 months without their disease getting worse compared with 2.8 months with ipilimumab.
Bolniki, zdravljeni z zdravilom Keytruda, so živeli do 5,6 meseca brez poslabšanja bolezni v primerjavi z 2,8 meseca v skupini z ipilimumabom.
Patients treated with Keytruda lived on average around 10 months compared with around 7 months with the other cancer medicines.
Bolniki, zdravljeni z zdravilom Keytruda, so v povprečju živeli približno deset mesecev v primerjavi s približno sedem mesecev pri bolnikih, ki so prejemali druga zdravila za zdravljenje raka.
In a study of 495 patients, patients treated with Keytruda who had high levels of PD-L1 lived on average for 11.6 months while those taking standard cancer treatments lived for 6.6 months.
V študiji, ki je zajela 495 bolnikov, so bolniki, zdravljeni z zdravilom Keytruda, pri katerih so bile s preiskavo ugotovljene večje količine beljakovine PD-L1, v povprečju živeli 11,6 meseca, bolniki, ki so prejemali standardna zdravila za zdravljenje raka, pa 6,6 meseca.
The side effects of Keytruda are mostly related to the activity of the immune system, which may cause inflammation of body organs and tissues and can be serious, although most side effects resolve with appropriate treatment or on stopping Keytruda.
Povzročijo lahko vnetje telesnih organov in tkiv ter so lahko resni, vendar je večino neželenih učinkov mogoče odpraviti z ustreznim zdravljenjem ali prekinitvijo zdravljenja z zdravilom Keytruda.
Keytruda is also effective in improving survival of patients with head and neck squamous cell carcinoma (HNSCC) that had spread or come back.
Zdravilo Keytruda je učinkovito tudi pri izboljšanju preživetja bolnikov s ploščatoceličnim rakom glave in vratu, ki se je razširil ali ponovil.
• a cancer affecting the head and neck known as head and neck squamous cell carcinoma (HNSCC),
• urotelijskega raka, tj. raka sečnega mehurja in sečil; • raka, ki prizadene glavo in vrat, imenovanega ploščatocelični rak glave in vratu;
In addition, patients who had Keytruda treatment lived on average for 8.8 months without the disease getting worse compared with 4.9 months for patients who were not given Keytruda.
Poleg tega so bolniki, ki so jemali zdravilo Keytruda, brez poslabšanja bolezni v povprečju živeli 8,8 meseca, bolniki, ki tega zdravila niso prejemali, pa 4,9 meseca.
• classical Hodgkin lymphoma, a cancer of the white blood cells,
• nedrobnoceličnega pljučnega raka, tj. vrste pljučnega raka; • klasičnega Hodgkinovega limfoma, tj. raka belih krvnih celic;
Also, up to 74% of patients treated with Keytruda lived for at least 12 months after the start of their treatment compared with 59% of patients on ipilimumab.
Prav tako je po začetku zdravljenja v skupini bolnikov, ki so prejemali zdravilo Keytruda, do 74 % bolnikov živelo vsaj 12 mesecev, v skupini z ipilimumabom pa je bilo takih bolnikov 59 %.
Keytruda contains the active substance pembrolizumab.
Zdravilo Keytruda vsebuje učinkovino pembrolizumab.
In a second study of 370 patients who could not be treated with cisplatin-containing medicines, Keytruda produced a complete or partial remission (clearing) of the cancer in 108 patients (29%); a complete remission occurred in 30 (8%) of them, meaning they no longer had any signs of cancer.
V glavni študiji s 370 bolniki, ki niso mogli prejemati zdravil s cisplatinom, je zdravilo Keytruda delno ali v celoti uničilo raka pri 108 bolnikih (29 %).
In a main study of 210 patients, Keytruda produced a complete or partial remission (clearing) of the cancer in 145 patients (69%); a complete remission occurred in 47 (22%) of them, meaning they no longer had any signs of cancer.
V glavni študiji z 210 bolniki je zdravilo Keytruda delno ali v celoti uničilo raka pri 145 bolnikih (69 %).
In addition, patients taking Keytruda alone lived on average 12.3 months compared with 10.3 months for patients taking other standard treatments.
Poleg tega so bolniki, ki so jemali zdravilo Keytruda kot samostojno zdravilo, v povprečju živeli 12,3 meseca, bolniki, ki so prejemali druga standardna zdravljenja, pa 10,3 meseca.
Patients in the Keytruda group lived on average for around 6 months without their disease getting worse compared with 4.8 months for patients in the placebo group.
Bolniki, ki so prejemali zdravilo Keytruda, so živeli povprečno šest mesecev brez poslabšanja bolezni, v primerjavi s 4,8 meseca pri bolnikih iz skupine, ki je prejemala placebo.
In a study looking at around 1,000 previously treated patients, patients lived longer with Keytruda given alone (around 11 months) than with another cancer medicine called docetaxel (around 8 months) and the period during which the disease did not get worse was around 4 months with both treatments.
V študiji, v katero je bilo vključenih približno 1 000 predhodno zdravljenih bolnikov, so bolniki, ki so jemali samo zdravilo Keytruda, živeli dlje (približno 11 mesecev) kot tisti, ki so jemali drugo zdravilo za zdravljenje raka, docetaksel (približno osem mesecev).
Keytruda is also effective in improving survival of patients with renal cell cancer.
Zdravilo Keytruda je bilo učinkovito tudi pri podaljševanju preživetja bolnikov z rakom ledvičnih celic.
Patients taking the Keytruda combination lived on average for 13.6 months compared with 10.4 months for patients taking other standard treatments.
Bolniki, ki so prejemali zdravilo Keytruda v kombinaciji z navedeno kemoterapijo, so v povprečju živeli 13,6 meseca, bolniki, ki so prejemali druga standardna zdravljenja, pa 10,4 meseca.
Kidney cancer
Nedrobnocelični pljučni rak
In some patients, tumours have to produce a high level of PD-L1 for the medicine to be effective.
Pri nekaterih bolnikih je zdravilo učinkovito samo, če njihovi tumorji tvorijo večje količine beljakovine PD-L1.
In a second lung cancer study of 305 patients whose tumours tested strongly for PD-L1 who had not been treated before, patients on Keytruda lived for around 10 months without their disease getting worse compared with 6 months in patients receiving platinum-based chemotherapy.
V drugi študiji pljučnega raka, v katero je bilo vključenih 305 bolnikov, pri katerih so bile s preiskavo ugotovljene večje količine beljakovine PD-L1 v tumorjih in ki pred tem še niso bili zdravljeni, so bolniki,
Keytruda is a cancer medicine used to treat:
Keytruda je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje: • melanoma, tj. vrste kožnega raka;
--1 1 dose (0.5 ml) contains:
--1 En odmerek (0,5 ml) vsebuje:
Recombinant lipidated fHbp (factor H binding protein) Produced in Escherichia coli cells by recombinant DNA technology Adsorbed on aluminium phosphate (0.25 milligram aluminium per dose)
adsorbirano na aluminijev fosfat (0,25 milligramov aluminija na odmerek)
Neisseria meningitidis serogroup B fHbp subfamily B
fHbp iz Neisseria meningitidis serološke skupine B, podskupina B
Neisseria meningitidis serogroup B fHbp subfamily A
fHbp iz Neisseria meningitidis serološke skupine B, podskupina A
1 pre-filled syringe with needle
1 napolnjena injekcijska brizga z iglo
The recommended dose is 0.14 mg per kilogram body weight, once a day for five days.
Priporočeni odmerek je 0,14 mg na kilogram telesne mase enkrat dnevno pet dni.
The marketing authorisation was renewed on 14 April 2009.
Dovoljenje za promet je bilo obnovljeno 14. aprila 2009.
In the main study, 97% of the patients had either complete or partial remission (60 out of 62), and 76% had complete remission (47 out of 62).
V glavni študiji je 97 % bolnikov doseglo popolno ali delno remisijo (60 od 62), 76 % ji je doseglo popolno remisijo (47 od 62).
Because cladribine has been used for a number of years, the company presented data from the published literature.
Ker se kladribin uporablja že več let, je družba predstavila podatke iz objavljene literature.
Other information about Litak:
Druge informacije o zdravilu Litak:
The main measures of effectiveness were the numbers of patients who had complete and partial remission following treatment.
Glavno merilo učinkovitosti je bilo število bolnikov s popolno oziroma delno remisijo po zdravljenju.
The most common side effects with Litak (seen in more than 1 patient in 10) are infections, pancytopenia or myelosuppression (low blood cell counts), purpura (bruising), immunosuppression (a weakened immune system), decreased appetite, headache, dizziness, abnormal breath and chest sounds, cough, nausea (feeling sick), vomiting, constipation, diarrhoea, rash, localised exanthema (skin eruptions), diaphoresis (excessive sweating), injection site reactions (pain and inflammation at the site of injection), fever, fatigue (tiredness), chills and asthenia (weakness).
Najpogostejši neželeni učinki zdravila Litak (opaženi pri več kot 1 bolniku od 10) so okužbe, pancitopenija ali mielosupresija (nizka raven krvnih celic), purpura (podplutbe), imunosupresija (oslabljen imunski sistem), zmanjšan apetit, glavobol, omotica, nenormalni dihalni zvoki in zvoki iz prsnega koša, kašelj, navzeja (slabost), bruhanje, zaprtje, driska, izpuščaj, lokalni eksantem (površinsko vnetje kože), diaforeza (čezmerno znojenje), reakcije na mestu injiciranja (bolečine in vnetje na mestu injiciranja), povišana telesna temperatura, utrujenost, mrazenje in astenija (šibkost).
The European Commission granted a marketing authorisation valid throughout the EU for Litak to Lipomed GmbH on 14 April 2004.
Evropska komisija je dovoljenje za promet z zdravilom Litak, veljavno po vsej Evropski uniji, odobrila družbi Lipomed GmbH dne 14. aprila 2004.
CdATP can also affect other cells, particularly other types of blood cell, which can cause side effects.
CdATP lahko vpliva tudi na druge celice, zlasti druge vrste krvnih celic, kar lahko povzroči neželene učinke.